(AOF) – The European Commission (EC) has approved Dupixent (dupilumab) in the European Union (EU) for the treatment of severe atopic dermatitis in children aged 6 months to 5 years as a candidate for systemic therapy. With this approval, Dupixent becomes the first and only targeted medicine indicated for the treatment of children in this age group in Europe and the United States. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.
Atopic dermatitis is a chronic skin disease with a type 2 inflammatory signature. Between 85% and 90% of patients develop the first symptoms before the age of 5 years and these symptoms often persist into adulthood.
These are characterized by intense and persistent itching and skin lesions that cover virtually the entire surface of the body, causing skin dryness, cracking, redness or dark skin, as well as the formation of crusts and oozing which are accompanied by an increased risk of skin infections.
© AOF
Legal disclaimer
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial exploitation or not, creation of a hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from the sources it considers the safest. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors in no way guarantee the absence of error and defects, even hidden ones, nor the exhaustive character or the lack of conformity for any use whatsoever of this data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember on the financial markets.
